Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer.

Ayumu MitsuyoshiMasayuki NagahashiHaruka KanaokaAoi OshiroYusa TogashiAkira HattoriJunko TsuchidaTomoko HiguchiArisa NishimukaiKeiko MuraseYuichi TakatsukaYasuo Miyoshi

Published in: International journal of clinical oncology (2024)

NLR at EOT with CDK4/6 inhibitors is a significant and independent prognostic marker for patients with ER-positive HER2-negative advanced breast cancer.

Keyphrases

prognostic factors
cell cycle
estrogen receptor
endoplasmic reticulum
breast cancer cells